We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.62 | -1.64% | 97.44 | 98.22 | 97.44 | 97.76 | 1,562,845 | 21:20:33 |
From Apr 2022 to Apr 2024
By Joshua Kirby
Novartis AG said Monday that it is appointing Gilbert Ghostine to chair the board of directors of its generics division Sandoz, which the drug maker is in the process of spinning off.
Mr. Ghostine has been chief executive of Geneva-based perfume maker Firmenich since 2014 and previously also held executive positions at drinks group Diageo PLC, Novartis said. He will become chairman of the Sandoz board following board and shareholder approval, the Swiss company said.
Novartis last year set out a plan to strip away Sandoz and focus on its core business, a process set to be completed in the second half of this year.
Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby
(END) Dow Jones Newswires
February 20, 2023 01:43 ET (06:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
